Medical therapy for pulmonary arterial hypertension - Updated ACCP evidence-based clinical practice guidelines

被引:367
作者
Badesch, David B.
Abman, Steven H.
Simonneau, Gerald
Rubin, Lewis J.
McLaughlin, Vallerie V.
机构
[1] Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA
[2] Childrens Hosp, Denver, CO 80218 USA
[3] Hop Antoine Beclere, F-92141 Clamart, France
[4] Univ Calif San Diego, San Diego, CA 92103 USA
[5] Univ Michigan, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
anticoagulation; arginine; beraprost; bosentan; calcium-channel blockers; endothelin; endothelin receptor antagonist; epoprostenol; idiopathic pulmonary arterial hypertension; iloprost; medical therapy; oxygen; primary pulmonary hypertension; prostacyclin; pulmonary arterial hypertension; pulmonary hypertension; secondary pulmonary hypertension; sildenafil; therapy; treatment; treprostinil; vasoreactivity; warfarin;
D O I
10.1378/chest.06-2674
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
A consensus panel convened by the American College of Chest Physicians developed guidelines for the treatment of pulmonary arterial hypertension (PAH) that were published in 2004. Subsequently, several important clinical trials have been published, and new treatments have received regulatory approval. in addition, add-on and combination therapy are being explored, which promise to open new therapeutic avenues. This article, taking into consideration studies published prior to September 1, 2006, provides an update to the previously published guidelines. The original guidelines have been summarized, a discussion of new studies has been added, and the treatment algorithm has been revised to take into account recent developments in therapy. This update provides evidence-based treatment recommendations for physicians involved in the care of patients with PAH. Due to the complexity of the diagnostic evaluation required and the treatment options available, referral of patients with PAH to a specialized center continues to be strongly recommended.
引用
收藏
页码:1917 / 1928
页数:12
相关论文
共 33 条
  • [1] Pulmonary artery hypertension and sleep-disordered breathing - ACCP evidence-based clinical practice guidelines
    Atwood, CW
    McCrory, D
    Garcia, JGN
    Abman, SH
    Ahearn, GS
    [J]. CHEST, 2004, 126 (01) : 72S - 77S
  • [2] Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial
    Badesch, DB
    Tapson, VF
    McGoon, MD
    Brundage, BH
    Rubin, LJ
    Wigley, FM
    Rich, S
    Barst, RJ
    Barrett, PS
    Kral, KM
    Jöbsis, MM
    Loyd, JE
    Murali, S
    Frost, A
    Girgis, R
    Bourge, RC
    Ralph, DD
    Elliott, CG
    Hill, NS
    Langleben, D
    Schilz, RJ
    McLaughlin, VV
    Robbins, IM
    Groves, BM
    Shapiro, S
    Medsger, TA
    Gaine, SP
    Horn, E
    Decker, JC
    Knobil, K
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) : 425 - +
  • [3] Medical therapy for pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines
    Badesch, DB
    Abman, SH
    Ahearn, GS
    Barst, RJ
    McCrory, DC
    Simonneau, G
    McLaughlin, VV
    [J]. CHEST, 2004, 126 (01) : 35S - 62S
  • [4] Sitaxsentan therapy for pulmonary arterial hypertension
    Barst, RJ
    Langleben, D
    Frost, A
    Horn, EM
    Oudiz, R
    Shapiro, S
    McLaughlin, V
    Hill, N
    Tapson, VF
    Robbins, IM
    Zwicke, D
    Duncan, B
    Dixon, RAF
    Frumkin, LR
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) : 441 - 447
  • [5] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
    Barst, RJ
    Rubin, LJ
    Long, WA
    McGoon, MD
    Rich, S
    Badesch, DB
    Groves, BM
    Tapson, VF
    Bourge, RC
    Brundage, BH
    Koerner, SK
    Langleben, D
    Keller, CA
    Murali, S
    Uretsky, BF
    Clayton, LM
    Jobsis, MM
    Blackburn, SD
    Shortino, D
    Crow, JW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) : 296 - 301
  • [6] Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
    Barst, Robyn J.
    Langleben, David
    Badesch, David
    Frost, Adaani
    Lawrence, E. Clinton
    Shapiro, Shelley
    Naeije, Robert
    Galie, Nazzareno
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) : 2049 - 2056
  • [7] Bharani Anil, 2003, Indian Heart J, V55, P55
  • [8] Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
    Channick, RN
    Simonneau, G
    Sitbon, O
    Robbins, IM
    Frost, A
    Tapson, VF
    Badesch, DB
    Roux, S
    Rainisio, M
    Bodin, F
    Rubin, LJ
    [J]. LANCET, 2001, 358 (9288) : 1119 - 1123
  • [9] Surgical treatments/interventions for pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines
    Doyle, RL
    McCrory, D
    Channick, RN
    Simonneau, G
    Conte, J
    [J]. CHEST, 2004, 126 (01) : 63S - 71S
  • [10] Ambrisentan therapy for pulmonary arterial hypertension
    Galié, N
    Badesch, D
    Oudiz, R
    Simonneau, G
    McGoon, MD
    Keogh, AM
    Frost, AE
    Zwicke, D
    Naeije, R
    Shapiro, S
    Olschewski, H
    Rubin, LJ
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (03) : 529 - 535